All Articles

COMPASS Pathways And Greenbrook Are Partnering Up For Psychedelic Therapies

January 6, 2024
x min read

One of the most important psychedelic drug discovery companies in the world is starting to prepare for how psychedelic assisted therapies will actually reach patients in a clinical setting.

What’s happening:

  • Psychedelic biotechnology company COMPASS Pathways (NASDAQ: CMPS) has entered into a new multi year research collaboration with Greenbrook TMS (NASDAQ: GNBH)
  • The focus of the partnership between COMPASS and Greenbrook will be exploring potential ways to integrate psychedelic assisted therapies in a clinical setting and ensure the best patient outcomes possible

Why it matters:

  • COMPASS Pathway’s lead drug candidate COMP360 is a synthetic psilocybin compound meant to be administered with the guidance of a therapist
  • Greenbrook has an extensive clinical network across the United States, with many of their existing patients being a potential future fit for COMP360
  • Beginning to build data based frameworks for how psychedelic assisted therapies will actually be administered is a critical step forward for psychedelic therapeutics integrating into existing healthcare infrastructure

Going deeper:

  • COMP360 is currently in a Phase III trial for Treatment Resistant Depression after overwhelmingly positive results from their Phase I and Phase II trials
  • The FDA has already designated COMP360 as a “Breakthrough Therapy” for Treatment Resistant Depression
  • Upon completion of the Phase III clinical trial, COMPASS Pathways intends to seek FDA approval for being able to administer COMP360 in clinics across the United States

By the numbers:

  • In the successful Phase II clinical trial for COMP360, patients who received a single 25mg dose of COMP360 saw significant improvements in their symptoms within just 3 weeks

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.